TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02421341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheters
Description: A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Catheters
Description: A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: You will be asked to exercise, ride a stationary bike, at maximal exertion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: You will be asked to exercise, ride a stationary bike, at maximal exertion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA
Description: During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: DEXA
Description: During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
Study: NCT04478344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided hydrodissection of superior cluneal nerve
Description: Intervention procedure: hydrodissection to the superior cluneal nerve entrapment; Device for guidance of injection: high-resolution ultrasound ; Drug for injection: a mixture of 1 mL of 50% dextrose, 4 mL of 1% lidocaine, and 5 mL of 0.9% normal saline
Study: NCT01764139

Intervention type: PROCEDURE
Intervention: Blood sampling
Study: NCT01155128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise aerobic
Description: The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise aerobic
Description: The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
Study: NCT00864695

Intervention type: OTHER
Intervention: Supportive care
Description: protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
Study: NCT03562988

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin C gummy
Description: vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin C gummy
Description: vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin C tablet
Description: vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin C tablet
Description: vitamin C
Study: NCT02421341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Tests
Description: During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Function Tests
Description: During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw
Description: You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemosensitivity Test
Description: Using a bag you breath in and out your own air.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chemosensitivity Test
Description: Using a bag you breath in and out your own air.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01027533

Intervention type: OTHER
Intervention: Implantation of a multifocal Intraocular lens
Description: Bilateral implantation of a multifocal IOl

Intervention type: OTHER
Intervention: Implantation of a multifocal Intraocular lens
Description: Bilateral implantation of a multifocal IOl
Study: NCT00501982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant alfa (Curosurf®)
Study: NCT02934009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal nuclear magnetic resonance (NMR)-profile measurement
Description: Nuclear magnetic resonance (NMR)-profile measurement of the dermis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal nuclear magnetic resonance (NMR)-profile measurement
Description: Nuclear magnetic resonance (NMR)-profile measurement of the dermis
Study: NCT02096510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solu-Cortef
Description: administration by pump for minimum 2 weeks
Study: NCT04057625

Intervention type: DEVICE
Group type: OTHER
Intervention: transthoracic ultrasound
Description: using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
Study: NCT05588635

Intervention type: OTHER
Intervention: Identification of predictive factors
Description: Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).

Intervention type: OTHER
Intervention: Identification of predictive factors
Description: Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
Study: NCT01276171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Participants will place arterial line using ultrasound technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Participants will place arterial line using doppler technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: Participants will place arterial line using Palpation technique
Study: NCT01688024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT03723187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: experimental group use normal saline sealing tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline+heparin
Description: normal saline+heparin(Currently, Regular used in hospital)
Study: NCT02322710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgotul: Low-adherent dressing
Study: NCT00773838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Four 100 mg vorinostat capsules orally, once daily (QD) by mouth on Days 1-14 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2, IV injection QD on Days 1, 4, 8, and 11 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Five 4 mg Dexamethasone tablets orally, QD on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if PD is observed after 2 treatment cycles or if NC to disease is observed after 4 treatment cycles.
Study: NCT05014633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EI skills training
Description: EI training sessions were held and managed by two experienced instructors selected from medical education specialists with sufficient experience in conducting EI training. Both instructors attended the sessions, presented the content, videos, slides, and brochures with the help of each other, and managed related scenarios in each session.
Study: NCT01494493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS/allograft bone dowel
Description: The rhBMP-2/ACS used in conjunction with an allograft bone dowel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/allograft bone dowel
Description: An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
Study: NCT03800420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S first and then Placebo
Description: Total 16 week treatment period: The subject takes BBT-401-1S, QD for the first 12 weeks, then placebo for the last 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first and then BBT-401-1S
Description: Total 16 week treatment period: The subject takes the placebo, QD for the first 8 weeks, then BBT-401-1S for the last 8 weeks.
Study: NCT02691585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: A raga will be played for 10 minutes \& data collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: A raga will be played for 10 minutes \& data collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: A raga will be played for 10 minutes \& data collected.
Study: NCT02322710

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TulleGras M.S.: Vaseline gauze
Study: NCT03473093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: One group will receive oral pregabalin with morphine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One group will receive morphine infusion 20 microgram/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One group will receive morphine infusion 20 microgram/kg/h
Study: NCT00926692

Intervention type: OTHER
Intervention: Blood draw
Description: Subject will have blood draw.
Study: NCT02096510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortef
Description: tablet treatment 2 ro 3 times per day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef
Description: tablet treatment 2 ro 3 times per day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortef
Description: tablet treatment 2 ro 3 times per day for 14 days
Study: NCT04487262

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac surgery
Description: Elective open heart surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac surgery
Description: Elective open heart surgery
Study: NCT01124929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNTCP Category I treatment for 6 months
Description: 2H3R3Z3 E3 + 4H3R3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RNTCP Category I treatment for 9months
Description: 2H3R3Z3 E3 + 7H3R3
Study: NCT02917564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
Description: After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham - Participants will not recieve the Triamcinolone Acetonide
Description: Patients will be given a sham.
Study: NCT02576145

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT
Description: Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT
Description: Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show \>=1.5 fold increase in lymphocyte proliferative response but have a humoral response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: The fifth dose (1 milligram per kilogram \[mg/kg\]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH
Description: KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: KLH
Description: KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
Study: NCT03267628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine as well as local anaesthetic in Blocks
Description: A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine as well as local anaesthetic in Blocks
Description: A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine as well as saline in Block
Description: 150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine as well as saline in Block
Description: 150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline intrathecal as well as saline in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline intrathecal as well as saline in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
Study: NCT02060916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ320
Description: Single-center pilot study, open label dose escalation design
Study: NCT00117052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
Study: NCT00878761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-100
Description: SC, single dose followed by multiple dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-100
Description: SC, single dose followed by multiple dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-100
Description: SC, single dose followed by multiple dose
Study: NCT00179387

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind-Body Psychotherapy Group
Description: Psycho-educational group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind-Body Psychotherapy Group
Description: Spiritual-Existential Group
Study: NCT02266680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Treatment Group
Description: The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
Study: NCT01549769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl
Description: Oral, once daily
Study: NCT00878761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-100
Description: SC, single dose followed by multiple dose
Study: NCT03267628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline intrathecal as well as local anaesthetic in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline intrathecal as well as local anaesthetic in Blocks
Description: 0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
Study: NCT01180569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles
Study: NCT04424069

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgery
Description: Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgery
Description: Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgery
Description: Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
Study: NCT05856604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Weekly individual (one2one) Music Therapy intervention lasting 4 months (n=16 sessions).~Behavioral: Music Therapy Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has been shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling
Description: Weekly individual (one2one) Storytelling intervention lasting 4 months (n=16 sessions).~Behavioural: Storytelling is a non-pharmacological activity, in which a professional activity coordinator reads different stories (e.g., poems, novels) to the participants and used them to initiate a possible conversation.
Study: NCT04424069

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive surgery
Description: Myopic patients seeking refractive surgery will be assigned to the study groups to assess the change in myopic and papillary perfusion in these different prodecures
Study: NCT04090541

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rigid Tape
Description: Non-Elastic Tape

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology Tape
Description: Tape can be elongate only one direction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical Tape
Description: Tape can be elongate only two direction